1888. Outcomes of Ceftaroline Fosamil q8h vs q12h Dosing Frequency for High-Burden, Gram-positive Infections
Session: Poster Abstract Session: Clinical Study with New Antibiotics and Antifungals
Saturday, October 7, 2017
Room: Poster Hall CD

Background: High-burden, Gram-positive (HBGP) infections such as bacteremia, endocarditis, hospital-acquired pneumonia/ventilator-associated pneumonia [HAP/VAP], and osteomyelitis are associated with substantial morbidity and mortality. CAPTURE, a retrospective, phase 4 study, describes clinical use of ceftaroline fosamil (CPT-F) in the United States. Clinical outcomes of patients with HBGP infections treated with CPT-F q8h (every 8 hours) vs q12h (every 12 hours) are presented.

Methods: Data including patient demographics, medical history, disease characteristics, antibiotic use, pathogens isolated, and clinical outcome were collected between September 2013 and February 2015 by review of randomly ordered patient charts from participating sites in the US. Clinical success was defined as discontinuation of CPT-F following clinical cure with no further need for antibiotic or clinical improvement with switch to another antibiotic.

Results: In total, 541 patients with HBGP infections were treated with CPT-F (q8h, 22% [117/541]; q12h, 78% [424/541]). Demographics and baseline characteristics were well balanced; however, patients who received q8h dosing were more likely to have a diagnosis of bacteremia or endocarditis (P<0.001) and have infection with MRSA (P<0.001; Figure1). Methicillin-resistant S.aureus was the most commonly isolated organism in the q8h (96/117; 82%) and q12h (255/424; 60%) groups. The mean (SD) duration of CPT-F therapy was 13.6 (10.8) and 8.4 (7.4) days in patients receiving q8h and q12h CPT-F, respectively. Monotherapy was used in 57% (311/541) of patients. The most commonly used concurrent antibiotics were vancomycin (12%; 64/542) and daptomycin (11%; 62/542). Clinical success rates of all patients with HBGP infections treated with CPT-F was >70% regardless of dosing frequency (Figure 2). Overall clinical success in q8h vs q12h treated individuals was 79% (92/117) and 83% (350/424), respectively. Discontinuation due to an adverse event occurred at a similar rate (q8h, 3% vs q12h, 2%).

Conclusion: High rates of clinical success were observed in patients treated with CPT-F q8h or q12h for HBGP infections, regardless of dose frequency despite more patients having had MRSA infection and/or bacteremia in the q8h cohort.

Sonia Rao, PharmD1, Jennifer Hayes, PharmD1, Keith S. Kaye, MD, MPH2, Jie Chen, PhD1 and Leonard Johnson, MD3, (1)Allergan plc, Jersey City, NJ, (2)Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, (3)Infectious Diseases, Saint John Hospital and Medical Center; Ascension, Grosse Pointe Woods, MI

Disclosures:

S. Rao, Allergan plc: Employee , Salary

J. Hayes, Allergan plc: Employee , Salary

K. S. Kaye, Allergan plc: Consultant , Consulting fee

J. Chen, Allergan plc: Employee , Salary

L. Johnson, Allergan plc: Investigator , Research support

<< Previous Abstract | Next Abstract

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.